Questcor Pharmaceuticals acquires rights to Synacthen®
Questcor Pharmaceuticals, Inc. today announced it has acquired rights to develop Synacthen ® and Synacthen Depot in the US from Novartis Pharma AG and Novartis AG. Subject to certain closing conditions, Questcor has also acquired rights to Synacthen ® and Synacthen Depot ® in certain countries outside the US Available in more than forty countries for multiple indications, Synacthen is a synthetic 24 amino acid melanocortin receptor agonist.
Quest Software, which develops management software for business and industrial uses, agreed to be taken private by Insight Venture, a New York venture capital and private equity firm.